Bio-Path Holdings Inc (NASDAQ: BPTH) is having a great start to the trading session in the pre-market hours this morning, and for good reason. The company presented positive pre-clinical data, exciting investors and sending the stock screaming for the top. Today, we’ll talk about:
- The data presentation;
- what we’re seeing from BPTH stock as a result; and
- what we’ll be watching for ahead.
BPTH Stock Gains On Data Presentation
As mentioned above, Bio-Path Holdings is having a great day in the market today after the company announced positive pre-clinical data. The data came by way of a poster presentation at the American Association for Cancer Research.
The data presented came from preclinical studies that support the potential of BP1003. The asset is a novel lipsome-incorporated STAT3 oligodeoxynucleotide inhibitor that is being developed for the treatment of pancreatic cancer, non-small cell lung cancer, and acute myelogenous leukemia.
In the release, BPTH said that the poster highlights four antisense oligo sequences directed against STAT3 mRNA identified by the company and manufactured using DNAbilize antisense RNAi nanoparticle technology.
In a press release, the company outlined several points of data that suggest that the drug may be effective in all three cancer indications mentioned above. In a statement, Peter Nielsen, CEO at BPTH, had the following to offer:
We believe these data suggest that between our two drug candidates, BP1003 and prexigebersen, Bio-Path will be able to treat human pancreatic tumors. The Company expects to initiate a Phase I study of prexigebersen for the treatment of solid tumors in 2019, including a cohort of metastatic pancreatic cancer patients. We plan to complete Investigational New Drug (IND) enabling studies in 2019 and to file an IND application for a Phase I study of BP1003 for the treatment of pancreatic cancer in 2020.
These data are very encouraging and suggest that our two drug candidates, BP1003 and prexigebersen, are active against pancreatic cancer which is often treatment refractory and lethal. As with prexigebersen, studies to date have shown BP1003 to be generally safe and well-tolerated in preclinical models. We believe there is a great potential for the additional development of BP1003 as a treatment for NSCLC, AML and a variety of metastatic cancers.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. When it comes to Bio-Path Holdings, the news proved to be positive.
While the data presented was surrounding an asset that is still in early stages, should the asset prove to be effective in these indications, it could come with a very high value. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top.
As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:57), BPTH is trading at $20.69 per share after a gain of $1.01 per share or 5.13% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on BPTH. In particular, we’re interested in following the company’s continued work to develop BP1003 as the asset seems to come with promise, as well as the rest of its relatively robust pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!